Elektrofi, a Boston, MA-based biotechnology company focused on drug formulation and delivery innovations, raised $40m in Series B financing round.
The round was led by Marshall Wace and BVF Partners, with participation from Janus Henderson Investors and Logos Capital.
A portion of the proceeds will be used to establish a centralized GMP manufacturing line in support of multiple upcoming clinical trials. The company will also plan to double headcount over the next 12-18 months to accelerate development across a growing pipeline of licensed programs with leading pharma and biotech.
Led by Chase Coffman, CEO, Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. has developed a formulation platform that addresses the long-standing and unmet need for stabilized, highly concentrated biologics. Based on a proprietary microparticle technology, the platform enables patient-friendly small-volume injections for monoclonal antibodies, therapeutic proteins, and other large molecule drugs that are of growing importance to human health.